Washington
Q3 2026Lobbying Q3 None no reports
YoY n/a vs Q3 2025
Members 0 all time
Buys / sells 0 / 0 0 trades
CARL
CARLSMED, INC.$14.53 −0.08 (−0.55%)
Oct 23 4:00 PM ET · prev $14.61
Market cap
$398.9M
Small cap
Consensus
Buy
91% Buy or better · 11 analysts
Median target
$18.00
+24% · range $17.00–24.00
Next earnings
Nov 5
in 10 days · EPS est. −$0.39
1 year
+7.3%
from $13.54 · Oct 27
30 days
+2.5%
from $14.18
52-week range
$8.83–16.99
−14% from high · low Apr 29
Avg volume 20D
74.5K
shares / day
Short interest
🔒 Subscribers only
Insider net
−$2.6M
0 buyers · 2 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
6
analyzed by SecBot
SecBot read BULLISH 5 reports · 90 days
Balance 0 bearish · 1 bullish · 4 neutral oldest → newest, height = score
Avg score ·High conf. 4/5 ·Next Earnings date, Nov 5, 2026
Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
No data for this timeframe.
- S Mar 2 1 insider sell $2.6M at $13.29
- A Jul 1 Needham initiates
- R Sep 15 A 10% owner of Carlsmed, Presidio Management Group XII, L.L.C., made…
- S Sep 30 to Oct 5 2 days of insider sells: $14.1K by 1 insider, avg $14.29
Signal stack
Where each data set points today.
- InsidersBEARISH
2 insiders sold $2.6M.
- InstitutionsBULLISH
Q2 2026: 13 added (0 new), 1 trimmed or exited.
- AnalystsBULLISH
10 of 11 rate it Buy or better. Every target is above the price.
- EstimatesRISING
Current-quarter EPS estimate −$0.395 → −$0.385 over 90 days. 1 up, 0 down in 30 days.
- TrendDOWNTREND
3% below its 50-day average.
Who's buying
13F· Q2 20260
new positions
0
exits
| Fund | Move | Value |
|---|---|---|
| CITADEL ADVISORS LLC | DOUBLED | $1.1M |
| JANE STREET GROUP, LLC | DOUBLED | $761.8K |
| GOLDMAN SACHS GROUP INC | DOUBLED | $655.2K |
| BNP PARIBAS FINANCIAL MARKETS | DOUBLED | $414.7K |
| MORGAN STANLEY | DOUBLED | $318.7K |
| Bank of New York Mellon Corp | ADD | $181.2K |
| UBS Group AG | ADD | $173.9K |
| BANK OF AMERICA CORP /DE/ | TRIM | $107.9K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
11 analysts 91% rate it Buy or better
12-month targets · 5 analysts
$14.53 $17.00 $18.00 $24.00
Price is below the lowest target. Median implies +24%.Targets as of Oct 27, 2026.
Recent actions
| Date | Firm | Rating |
|---|---|---|
| Oct 12, 2026 | BTIG MAINTAIN | Buy |
| Sep 28, 2026 | BTIG REITERATE | Buy |
| Aug 6, 2026 | Truist Securities MAINTAIN | Buy |
| Jul 1, 2026 | Needham INITIATE | Buy |
| May 6, 2026 | BTIG REITERATE | Buy |
Insider ledger
Form 4$0
bought · 0 insiders
$2.6M
sold · 2 insiders
| Date | Insider | Type | Value |
|---|---|---|---|
| Oct 5, 2026 | Bertolini Jeffrey Chief Operating Officer | EXERCISE | $4.4K |
| Oct 5, 2026 | Bertolini Jeffrey Chief Operating Officer | SELL | $10.7K |
| Sep 30, 2026 | Bertolini Jeffrey Chief Operating Officer | EXERCISE | $542.38 |
| Sep 30, 2026 | Bertolini Jeffrey Chief Operating Officer | SELL | $3.4K |
| Sep 28, 2026 | Heppenstall Richard CFO, Treasurer | AWARD | 89,286 sh |
| Sep 28, 2026 | Heppenstall Richard CFO, Treasurer | AWARD | 180,137 sh |
| Sep 8, 2026 | Bertolini Jeffrey Chief Operating Officer | AWARD | 50,000 sh |
| Jun 3, 2026 | Sidow Kevin Director | AWARD | 13,698 sh |
Earnings setup
EstimatesNov 5
reports in 10 days
−$0.39
EPS estimate, this quarter
+3%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
−$0.39590d
−$0.39560d
−$0.39530d
−$0.3957d
−$0.385Now
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.39 | -$0.41–-$0.36 | +2.5% | $19.2M |
| Next Q | -$0.34 | -$0.35–-$0.33 | +2.9% | $22.5M |
| Current FY | -$1.41 | -$1.45–-$1.37 | +3.8% | $76.7M |
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 15, 2026🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 14, 2026 SEC
Former officer Leonard M. Greenstein filed a Form 144 notice to sell 4,136 shares of Carlsmed common stock, with an…
144 — Impact 2/10
Oct 5, 2026 Insider
Bertolini Jeffrey acquired via exercise 747 shares
Chief Operating Officer @ $5.92 ($4.4K)
Oct 5, 2026 Insider
Bertolini Jeffrey sold 747 shares
Chief Operating Officer @ $14.39 ($10.7K)
Oct 2, 2026 Other
Sep 30, 2026 SEC Carlsmed, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CARLSBAD, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the
Carlsmed announced the departure of CFO Leo Greenstein (effective Sept 25, 2026) and the appointment of Richard…
8-K — Impact 4/10
Sep 30, 2026 Insider
Sep 28, 2026 SEC Bertolini Jeffrey acquired via exercise 243 shares
Chief Operating Officer @ $2.23 ($542.38)
Carlsmed announced the appointment of Richard Heppenstall as CFO, replacing Leo Greenstein. The company reaffirmed its…
PRESS-RELEASE — Impact 4/10
Jun 30, 2026 Inst.
CITADEL ADVISORS LLC — DOUBLED
101,726 shares ($1.1M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Recent
Oct 2, 2026
Press release
Carlsmed, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CARLSBAD, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company…
Oct 1, 2026
Press release
Carlsmed Appoints Tony Jarc as Chief Product and AI Officer
CARLSBAD, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company…
Sep 28, 2026
Earnings
Carlsmed Appoints Richard Heppenstall as Chief Financial Officer
Company Reaffirms Fiscal Year 2026 Guidance Company Reaffirms Fiscal Year 2026 Guidance
Sep 15, 2026
Press release
Carlsmed, Inc. Files Patent Infringement Lawsuit against DeGen Medical
CARLSBAD, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” ), a medical technology company pioneering AI-enabled…
Sep 8, 2026
Press release
Carlsmed, Inc. Announces Chief Operating Officer Appointment
CARLSBAD, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company…
SecBot reports
6 filings · 1 bullish · 0 bearish · 5 neutral- NEUTRAL 144Oct 14, 2026
Former officer Leonard M. Greenstein filed a Form 144 notice to sell 4,136 shares of Carlsmed…
This is a mandatory sell-to-cover transaction for tax purposes, not a discretionary insider sale. No material signal about the company's outlook. Monitor for any future discretionary Form 4 filings…
- NEUTRAL 8-KSep 30, 2026
Carlsmed announced the departure of CFO Leo Greenstein (effective Sept 25, 2026) and the…
CFO transition is orderly with a qualified replacement and no accounting red flags. The reaffirmed FY2026 guidance of $74M-$78M revenue (50% growth is the key signal — watch for upcoming CMS…
- NEUTRAL PRESS-RELEASESep 28, 2026
Carlsmed announced the appointment of Richard Heppenstall as CFO, replacing Leo Greenstein. The…
Monitor upcoming Q3 2026 earnings for initial impact of aprevo Lumbar CMS reimbursement (effective Oct 1) and product launches on revenue trajectory. The CFO transition is routine but Heppenstall's…
- BULLISH INSIDER-BUYSep 15, 2026
A 10% owner of Carlsmed, Presidio Management Group XII, L.L.C., made a single open-market purchase…
This is a strong bullish signal from a 10% owner deploying significant capital. Traders should monitor for potential positive catalysts such as upcoming earnings, product approvals, or strategic…
All CARL filing & press-release reports (6)
- 144 reportOct 14, 2026
- 8-K reportSep 30, 2026
- PRESS-RELEASE reportSep 28, 2026
- INSIDER-BUY reportSep 15, 2026
- EFFECT reportAug 24, 2026
- PRESS-RELEASE reportJul 22, 2026